Access to Healthcare | Novartis

Media Release
May 09, 2023
Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars
Media Release
May 04, 2023
Sandoz to exclusively commercialize six products in the US, reinforcing global leadership position in off-patent medicines
Media Release
Apr 03, 2023
Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation
Media Release
Mar 21, 2023
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
Media Release
Aug 25, 2022

Novartis will das Sandoz Geschäft durch eine hundertprozentige Ausgliederung als eigenständiges Unternehmen abspalten
Story
Dec 21, 2022
Compassionate use: Providing access to much needed treatments
Media Release
Nov 23, 2022
Novartis and Medicines for Malaria Venture announce decision to move to Phase 3 study for novel ganaplacide/lumefantrine-SDF combination in adults and children with malaria
Media Release
Jul 21, 2022
Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)
Media Release
Aug 25, 2022
Novartis announces intention to separate Sandoz business to create a standalone company by way of a 100% spin-off
Featured News
Oct 13, 2022
World Sight Day 2022: Raising awareness on the importance of eye health
Featured News
Sep 12, 2022
Novartis Hematology: Working to help ensure patients are getting the access they need
Media Release
Jun 23, 2022
Novartis renews commitment to neglected tropical disease and malaria elimination, investing USD 250 million over five years to research and develop new treatments